LeMaitre Vascular Inc (LMAT) director reports RSU and option awards

Rhea-AI Filing Summary

LeMaitre Vascular Inc reported that a company director received new equity awards in the form of common stock and stock options. On 12/10/2025, the director acquired 533 shares of common stock through a restricted stock unit award at a price of $0 per share, bringing direct beneficial ownership to 62,340 shares.

The disclosure also shows stock options covering 3,431 shares of common stock with an exercise price of $83.66 and an expiration date of 12/10/2030. The restricted stock units vest 33 1/3% on 12/1/2026, with the remainder vesting in equal annual installments over the next two years, while the options vest over three years at 33 1/3% on the first anniversary of 12/01/2025, with the balance vesting in equal annual installments over the following two years.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Connor John James

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/10/2025		A		533(1)	A	$0	62,340	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$83.66	12/10/2025		A		3,431		12/01/2025(2)	12/10/2030	Common Stock	3,431	$0	3,431	D

Explanation of Responses:

1. Represents a restricted stock unit award that vests on a time-based schedule as follows: 33 1/3% of the award vests on 12/1/2026, with the balance vesting in equal annual installments over the remaining two years.

2. This option is exercisable and vests over a three-year period at a rate of 33 1/3% on the first anniversary of the date listed in the table, with the balance vesting in equal annual installments over the remaining two years.

	/s/ Laurie A. Churchill, Attorney-in-fact	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did LeMaitre Vascular (LMAT) report on 12/10/2025?

A director of LeMaitre Vascular Inc reported acquiring 533 shares of common stock through a restricted stock unit award and stock options covering 3,431 shares on 12/10/2025.

How many LeMaitre Vascular (LMAT) shares does the director own after this transaction?

After the reported transaction, the director beneficially owns 62,340 shares of LeMaitre Vascular common stock, held in direct ownership.

What are the vesting terms of the restricted stock unit award for the LMAT director?

The restricted stock unit award of 533 units vests on a time-based schedule: 33 1/3% vests on 12/1/2026, with the remaining units vesting in equal annual installments over the following two years.

What are the terms of the stock options reported for the LeMaitre Vascular (LMAT) director?

The director holds stock options to buy 3,431 shares of common stock at an exercise price of $83.66, expiring on 12/10/2030. These options vest over three years at a rate of 33 1/3% on the first anniversary of 12/01/2025, with the balance vesting in equal annual installments over the next two years.

Is this LeMaitre Vascular (LMAT) insider filing for one person or multiple people?

The disclosure indicates that the Form 4 was filed by one reporting person, who is identified as a director of LeMaitre Vascular Inc.

How is the LMAT director’s transaction classified in the Form 4 tables?

In the non-derivative table, the transaction is shown as an acquisition of 533 shares of common stock at $0. In the derivative table, it is shown as an acquisition of 3,431 stock options linked to common shares, also at a price of $0 for the derivative security.